MSMarc T. Swartz

Marc T. Swartz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Marc T. Swartz has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk analysis in patients bridged to transplantation

    by Lawrence R McBride, Keith S Naunheim, Andrew C Fiore, Robert G Johnson, Debbie A Moroney, Jenny A Brannan, Marc T Swartz


  • Ventricular assist device support in patients with mechanical heart valves

    by Marc T Swartz, Gregory A Lowdermilk, Debra A Moroney, Lawrence R McBride


    • 1 March 1995
      • Vol. 14  (2) , 366-72

    Heart transplantation charges: status 1 versus status 2 patients.

    by T V Votapka, M T Swartz, J E Reedy, D P Lohmann, L R McBride, L W Miller, D G Pennington

    The current health care environment mandates closer scrutiny of health care dollar allocation. To better understand the distribution of heart transplantation costs, we reviewed hospital and physician billing of patients who underwent orthotopic heart transplantation between August 1988 and September 1993. This study is a retrospective review of 107 consecutive cases. Charges and clinical results of United Network for Organ Sharing status 1 patients (n = 46), including 17 bridge to transplantation patients, were compared with those of United Network for Organ Sharing status 2 patients (n = 57). Charges were converted to 1992 dollars. During the first 12 months of the study, 77% of heart transplantations were performed in United Network for Organ Sharing status 2 patients, whereas over the last 12-month period, 25% of the transplantations were performed in status 2 patients. No significant differences were found in age, gender, type of cardiomyopathy, or survival between the status 1 and status 2 groups. The length of hospitalization for the status 1 group ranged from 8 to 138 days (mean 49 days) as opposed to 5 to 82 days (mean 17.5 days) for the status 2 group (p < 0.0001). Pretransplantation hospital charges were significantly higher for the status 1 group ($47,917 to $341,215, mean $109,116) when compared with status 2 ($0 to $10,035, mean $250) (p < 0.0001). No significant difference was found in posttransplantation hospital charges between status 1 ($47,917 to $210,027, mean $95,379) and status 2 patients ($48,093 to $380,745, mean $102,265). Total charges were significantly higher (p < 0.0001) for the status 1 group ($89,910 to $512,331, mean $239,375) when compared with the status 2 group ($63,885 to $455,680, mean $128,594). Total transplantation charges for the study period were $18,341,108. This amount could have paid for 77 status 1 transplantations or 143 status 2 transplantations. If current trends continue and the donor pool remains the same, most transplant recipients will be status 1, resulting in a comparable number of transplantations performed at twice the charges.


    • 1 September 1994
      • Vol. 179  (3) , 318-20

    Noncardiac operations in patients supported with mechanical circulatory support devices.

    by T V Votapka, D G Pennington, L R McBride, D L Kaminski, C H Andrus, M T Swartz

    Recent advances in technology as well as refinements of patient selection criteria have improved results of ventricular assistance in patients with end-stage heart disease. With a "normal" cardiac output and the resultant improvement in end-organ perfusion, some patients revert to normal or near normal physiology. Seven patients supported with cardiac assist devices who have undergone general surgical, nonassist device related procedures with the assist device in place are presented. This is a historical review of seven cases. The surgical procedures included three cholecystectomies, one dialysis catheter placement, and one thoracoscopy. Six patients had Thoratec ventricular assist devices (Thoratec Laboratories Corp., Berkeley, CA) and one was supported with a Jarvik (Symbion, Inc., Tempe, AZ) total artificial heart. In one patient, postcholecystectomy bleeding was the only complication that may have been directly attributable to having an assist device in place. Four patients underwent successful transplantation and three patients died, two during support and one after transplantation. As heart transplant waiting lists become longer and when permanent ventricular assist devices become available, an increasing number of patients on ventricular assistance will have noncardiac related pathology requiring operative intervention. In our experience, patients supported on mechanical assist devices tolerated these procedures well.


    • 1 September 1994
      • Vol. 13  (5) , 803-10

    Eleven years' experience with the Pierce-Donachy ventricular assist device.

    by D G Pennington, L R McBride, L W Miller, M T Swartz

    During the last decade, mechanical circulatory support has been used in patients with cardiogenic shock refractory to conventional therapy. Since 1982, we supported 77 patients (78 implants) with Pierce-Donachy external pneumatic ventricular assist devices. Forty-two patients (35 after cardiotomy, four after heart transplantation, and three with acute infarction) 15 to 71 years of age (mean age 52 years) were supported for cardiac recovery. Left ventricular assist devices were used in 16 patients, right ventricular assist devices plus intraaortic balloon were used in nine, and biventricular assist devices were used in 17. Patients were supported 0.2 to 17 days (mean 4.4 days), 18 patients (43%) were weaned, and 11 (26%) survived. Complications included acute myocardial infarction (60%), bleeding (48%), infection (38%), and renal failure (24%). Bridging to transplantation was attempted in 35 patients (one patient underwent the procedure twice), 12 to 63 years of age (mean age 40 years). Left ventricular assist devices were used 19 times, and biventricular assist devices were used 17 times. Duration of support was 0.2 to 95 days (mean 24 days). All 20 patients who underwent transplantation were discharged. Of the 15 patients who did not undergo transplantation, two were weaned and survived, whereas the remaining 13 patients (who did not undergo transplantation because of complications) died with the device in place. In the patients in the bridge to transplantation group, bleeding occurred in 26%, infection in 55%, and renal failure in 15%. In the entire group of 77 patients, the incidence of ventricular assist device-related thromboembolism was 6%, but only 4% had neurologic deficits.(ABSTRACT TRUNCATED AT 250 WORDS)


    • 1 December 1992
      • Vol. 104  (6) , 1654

    Intraaortic balloon pumping in patients requiring cardiac operations. Risk analysis and long-term follow-up.

    by K S Naunheim, M T Swartz, D G Pennington, A C Fiore, L R McBride, P S Peigh, M G Barnett, K J Vaca, G C Kaiser, V L Willman

    The intraaortic balloon pump is usually the first mechanical device inserted for perioperative cardiac failure; however, little current information is available regarding short- and long-term effectiveness. From January 1983 through November 1990, 6856 adult patients underwent cardiac surgical procedures, 580 of whom (8.5%) had an intraaortic balloon inserted preoperatively (107 patients), intraoperatively (419 patients), or postoperatively (54 patients). There were 374 men and 206 women with a mean age of 63.9 years (range 19 to 88). Operations included 376 coronary artery bypass grafts, 100 mitral valve replacements (with or without bypass grafting), 70 aortic valve replacements (with or without bypass grafting), 15 double valve replacements (with or without bypass grafting), and 32 other procedures. There were 72 (12.4%) complications related to the balloon pump, of which 42 necessitated surgical intervention including thrombectomy (21), vascular repair (13), fasciotomy (2), aortic repair (1), and amputation (4). Operative mortality for patients supported by the balloon pump was 44%. Multivariate stepwise analysis of 27 parameters revealed six independent predictors of mortality: preoperative New York Heart Association class, transthoracic intraaortic balloon insertion (both p < 0.0001), preoperative administration of intravenous nitroglycerin, age, female gender, and preoperative balloon insertion (p < 0.001). Balloon-related complications were not predictive of death. Of the 326 hospital survivors, only 34 were lost to follow-up. There were 75 late deaths, the cause of which was cardiac in 41 (55%), noncardiac in 20 (27%), and unknown in 14 (19%). Actuarial survivals at 1, 5, and 9 years are 51%, 42%, and 33%. Of the 217 hospital survivors still alive and contacted, 81% were in class I (114) or II (60). These data demonstrate (1) operative mortality for patients requiring an intraaortic balloon in the perioperative period remains high, (2) perioperative risk factors can be identified, (3) complications related to the balloon pump do not affect survival, (4) operative survivors can achieve prolonged survival with excellent functional results, and (5) consideration for alternative methods of circulatory support is justified.


    • 1 March 1992
      • Vol. 11, 246-52

    Status I heart transplant patients: conventional versus ventricular assist device support.

    by J E Reedy, D G Pennington, L W Miller, L R McBride, D P Lohmann, N R Noedel, M T Swartz

    Since 1985, 59 United Network for Organ Sharing status I patients have been considered for heart transplantation. Thirty-four patients were supported with drugs and/or intraaortic balloon pump (IABP) (group I). Twenty-five patients were supported with ventricular assist devices (VADs, group II). Forty percent of the patients in each group died before transplantation. Of the 20 group I patients who underwent transplantation, all received inotropic drugs, and five also required IABPs. All 14 group II patients who underwent transplantation were bridged with VADs. No difference was found in age, sex, or cause of disease between the groups. Complications after transplantation were more common in group I. Fourteen group I patients (70%) and 14 group II patients (100%) were discharged from the hospital (p = 0.03). One year after transplantation, mean left ventricular ejection fraction by cardiac catheterization was 53% in group I (12 patients) and 72% in group II (11 patients; p = 0.0008). Although VAD support does not insure transplantation, it strongly favors transplantation survival in status I patients. These data further suggest an advantage of VAD support for long-term survival.


    • 1 October 1991
      • Vol. 37  (4) , 549-52

    Cost and reimbursement rates for investigational circulatory support.

    by M T Swartz, J E Reedy, D Lohmann, T Bennett, L R McBride, D G Pennington

    The clinical evaluation of investigational circulatory support devices has, for the most part, been financed with private funds. St. Louis University initiated a system in 1986 to bill for investigational circulatory support devices and care related to their use. Charges for hospitalization and rates of reimbursement were reviewed in 32 patients who received Thoratec (Thoratec Laboratories Corp., Berkeley, CA [N = 26]), Novacor (Baxter Healthcare Corp., Oakland, CA [N = 4]), or Symbion (Symbion Inc., Tempe, AZ [N = 2]) total artificial heart devices. Duration of support ranged from 0.2 to 440 days (mean 32). Total charges ranged from $43,115 to $1,335,691 (mean $221,716). Charges for the devices and technical support relating directly to their use ranged from $10,305 to $96,030 (mean $28,246). The mean percentage of reimbursement (total charges/total paid) was 67%. Whereas it was uncertain in some patients whether or not the devices were paid for, commercial insurers are willing to reimburse at a high percentage for the total cost of care.